about
Imaging markers for Alzheimer disease: which vs howHarmonized diagnostic criteria for Alzheimer's disease: recommendationsRegional distribution of nicotinic receptor subunit mRNAs in human brain: comparison between Alzheimer and normal brainNeuronal nicotinic receptors in the human brainRegional distribution of nicotinic receptors during prenatal development of human brain and spinal cordAge-dependent neuroplasticity mechanisms in Alzheimer Tg2576 mice following modulation of brain amyloid-β levelsDecreased nicotinic receptors in PC12 cells and rat brains influenced by fluoride toxicity--a mechanism relating to a damage at the level in post-transcription of the receptor genesΒ-amyloid 1-42 oligomers impair function of human embryonic stem cell-derived forebrain cholinergic neuronsImaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-BClinical validity of increased cortical uptake of amyloid ligands on PET as a biomarker for Alzheimer's disease in the context of a structured 5-phase development framework.Clinical validity of brain fluorodeoxyglucose positron emission tomography as a biomarker for Alzheimer's disease in the context of a structured 5-phase development framework.Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria.Positron emission tomography imaging and clinical progression in relation to molecular pathology in the first Pittsburgh Compound B positron emission tomography patient with Alzheimer's disease³H-deprenyl and ³H-PIB autoradiography show different laminar distributions of astroglia and fibrillar β-amyloid in Alzheimer brainNeural Stem Cell Transplant-Induced Effect on Neurogenesis and Cognition in Alzheimer Tg2576 Mice Is Inhibited by Concomitant Treatment with Amyloid-Lowering or Cholinergic α7 Nicotinic Receptor DrugsA critical discussion of the role of neuroimaging in mild cognitive impairment.PET imaging of amyloid in Alzheimer's disease.Apolipoprotein E epsilon4 allele, skin vessel reactivity and vascular risk factors in Alzheimer's disease.Apolipoprotein E varepsilon4 allele has an impact on vascular reactivity in Alzheimer's disease.Nicotinic receptor abnormalities of Alzheimer's disease: therapeutic implications.Functional studies of cholinergic activity in normal and Alzheimer disease states by imaging technique.Safety of lumbar puncture procedures in patients with Alzheimer's disease.Different cholinesterase inhibitor effects on CSF cholinesterases in Alzheimer patients.Early diagnosis of Alzheimer disease with positron emission tomography.Progression from mild cognitive impairment to Alzheimer's disease: effects of sex, butyrylcholinesterase genotype, and rivastigmine treatment.Development of ligands for in vivo imaging of cerebral nicotinic receptors.Ligands for in vivo imaging of nicotinic receptor subtypes in Alzheimer brain.Mechanisms of alcohol-nicotine interactions: alcoholics versus smokers.Neurotrophic and neuroprotective actions of (-)- and (+)-phenserine, candidate drugs for Alzheimer's disease.Tau PET imaging: present and future directions.Strategic roadmap for an early diagnosis of Alzheimer's disease based on biomarkers.Marked accumulation of 27-hydroxycholesterol in the brains of Alzheimer's patients with the Swedish APP 670/671 mutationMild cognitive impairment with suspected nonamyloid pathology (SNAP): Prediction of progressionAstrocytosis precedes amyloid plaque deposition in Alzheimer APPswe transgenic mouse brain: a correlative positron emission tomography and in vitro imaging study.Imaging the pathology of Alzheimer's disease: amyloid-imaging with positron emission tomography.Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis.Visualization of regional tau deposits using (3)H-THK5117 in Alzheimer brain tissue.Molecular imaging in Alzheimer's disease: new perspectives on biomarkers for early diagnosis and drug development.Mild cognitive impairment--beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment.Prevalence of amyloid PET positivity in dementia syndromes: a meta-analysis
P50
Q27001254-3E0D23EC-4CCF-4F93-BE6A-849A172E5B53Q27009157-D63AC09A-8FAC-46C6-AFD8-634A2BA985A7Q28139981-75146D16-0FEC-4257-98AA-B7041A5E1D36Q28141480-AC89593E-2F14-4A73-8550-B0FE3A8D7367Q28278637-BD8D2976-8F3F-4660-AB9F-2F8FE9F9C019Q28488088-5B13F02B-5E47-408E-B21F-28F0CE000765Q28575989-24FF0BED-F1E6-4A82-BA62-462D70424CB5Q28744126-449D0EC6-D895-4A59-9753-AC0867804532Q29012704-2DAEB6E5-33C1-49CB-A071-775642024E53Q30235197-128B4382-D2F0-4F04-9908-6AB5C92947F8Q30235199-15B4027F-BF2B-473D-AD77-2A0A49B4891BQ30458193-1C003835-4D59-4064-8D58-9D6E4991DDE7Q30497749-DCBD4F55-AB2B-4570-B3EF-4436FD2A2D32Q30542245-37A690D2-B032-4D8E-9E05-60DF8B69C652Q30659307-BCD986D4-E3E4-4B0D-9961-40F590665FD8Q30772153-42CA2248-1106-49D6-8646-81774565CD3EQ30953216-8AB3B989-12D6-497D-8D5C-EE9714A907DCQ30953216-F81E04CD-5F5F-4FDC-9E46-A982267ABD5BQ31112931-DB26C386-8500-4D9F-AFFA-46C759A9B282Q31848662-0545E619-EC01-4174-B6E9-632147A611E3Q32077061-3C8B536F-DF75-477D-8DE8-C455E44B004AQ32077061-E6CCE935-1C30-4F98-8229-40C0BBBD6670Q33195555-599AA589-73E5-4523-A530-D425DEE4FC92Q33195555-DF7CFAB2-4A3E-438B-BB39-199DAB2E7056Q33671485-76DA6B2A-50E5-4C96-A091-0A500E0A782DQ33715239-E7BC50B1-161F-4E9C-86CC-9348068A60BFQ33941265-4C4BCEFF-F06D-49C9-9B07-A3261393CA76Q33968308-B44A4840-B94E-402C-B3E9-84D41A590EB7Q34002779-682D778C-550D-41E0-A2BC-488E01202FF1Q34191606-2F915DD9-7500-4044-9729-89668043E7C8Q34272834-49182CCB-98ED-49BD-9721-5854A0DCB550Q34575780-9C6F3BD9-F55C-4B79-A60A-48495081208DQ34680852-482A7CEA-C4CB-4A66-A0AD-25A89332E754Q34682521-92C3F06D-73FC-4EA3-A189-B53D8E5DE65CQ34776197-D8C17379-61C5-47D7-B5E1-3984D36A6B40Q35106472-5D6F783A-8233-4B84-A010-4BED4305CB24Q35582909-D6853C00-C8E4-4EA3-ACBB-773DC54D762AQ35692953-6B8B65D8-04FD-4AA5-B6AF-8F968E4ACE6CQ35800785-0AC3739D-9201-42C8-8812-64AC4AC28DCFQ35810005-E1448854-2B56-458A-98C1-AF70FBFB62F7
P50
description
Zweeds onderzoekster
@nl
hulumtuese
@sq
researcher
@en
հետազոտող
@hy
name
Agneta Nordberg
@ast
Agneta Nordberg
@en
Agneta Nordberg
@es
Agneta Nordberg
@nl
Agneta Nordberg
@pt
Agneta Nordberg
@sl
type
label
Agneta Nordberg
@ast
Agneta Nordberg
@en
Agneta Nordberg
@es
Agneta Nordberg
@nl
Agneta Nordberg
@pt
Agneta Nordberg
@sl
prefLabel
Agneta Nordberg
@ast
Agneta Nordberg
@en
Agneta Nordberg
@es
Agneta Nordberg
@nl
Agneta Nordberg
@pt
Agneta Nordberg
@sl
P106
P21
P27
P31
P496
0000-0001-7345-5151